<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239963</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003371</org_study_id>
    <nct_id>NCT04239963</nct_id>
  </id_info>
  <brief_title>Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression</brief_title>
  <official_title>Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of the present study is to evaluate the effect of a subanesthetic dose&#xD;
      of ketamine 24-hour post-injection on resting state functional connectivity, cognitive&#xD;
      control, and reward learning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major Depressive Disorder (MDD) participants with treatment-resistant depression (TRD) will&#xD;
      be recruited from McLean's Ketamine clinic. Suitability for Ketamine treatment will be&#xD;
      determined as typically done by the service - through evaluation by the clinicians on the&#xD;
      staff of the Ketamine Service who perform psychiatric consultations and assessments for&#xD;
      Ketamine suitability. Potential subjects will be informed about the study only after they&#xD;
      have received a positive consultation at the clinic and have already agreed to receive the&#xD;
      treatment.&#xD;
&#xD;
      This study consists of a set of questionnaires, urine drug screen, and electroencephalogram&#xD;
      (EEG) recordings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feedback-related positivity (FRP) amplitudes over frontocentral scalp regions in response to rewarded trials versus no-reward trials</measure>
    <time_frame>Baseline</time_frame>
    <description>Relative FRP response is the primary outcome measure for the probabilistic reward task (PRT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-related negativity (ERN) amplitudes over frontocentral scalp regions in response to correct trials versus incorrect trials.</measure>
    <time_frame>Baseline</time_frame>
    <description>Relative ERN response is the primary outcome measure for the flanker task.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Performance on the Probabilistic Reward Task (PRT)</measure>
    <time_frame>Baseline</time_frame>
    <description>The Probablilistic Reward Task operationalizes positive reinforcement learning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Performance on the Flanker Task</measure>
    <time_frame>Baseline</time_frame>
    <description>The Flanker Task is a cognitive task that measures response inhibition to assess the ability to suppress responses that are inappropriate in a particular context.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rumination</measure>
    <time_frame>Baseline</time_frame>
    <description>Severity of rumination will be assessed using the Rumination Response Scale (RRS). The RRS has a minimum score of 22 and a maximum score of 88. Higher scores indicate higher degrees of ruminative symptoms.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Subjects who have no history of clinical depression or other psychological disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current MDD</arm_group_label>
    <description>Subjects experiencing a current episode of Major Depressive Disorder.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to recruit 30 TRD individuals with current MDD without psychotic features and 30&#xD;
        demographically matched healthy controls. All participants will be ketamine-naïve.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (MDD Subjects):&#xD;
&#xD;
          -  All genders, races, and ethnic origins, aged between 18 and 64;&#xD;
&#xD;
          -  DSM-5 diagnostic criteria for MDD (diagnosed with the use of the Structured Clinical&#xD;
             Interview for DSM-5 (SCID-5));&#xD;
&#xD;
          -  A score of ≥32 on the Inventory of Depressive Symptomatology-Clinician Rated&#xD;
             (IDS-C30).&#xD;
&#xD;
          -  Capable of providing written informed consent, and fluent in English;&#xD;
&#xD;
          -  Right-handed;&#xD;
&#xD;
          -  Treatment Resistant (as assessed using the MGH Antidepressant Response Questionnaire)&#xD;
&#xD;
          -  Have already decided to receive ketamine treatment as part of their standard clinical&#xD;
             care&#xD;
&#xD;
        Inclusion Criteria (Control Subjects):&#xD;
&#xD;
          -  All genders, races, and ethnic origins, aged between 18 and 64;&#xD;
&#xD;
          -  Absence of medical, neurological, and psychiatric illness (including alcohol and&#xD;
             substance abuse), as assessed by subject history and a structured clinical interview&#xD;
             (SCID-I/NP);&#xD;
&#xD;
          -  A baseline Quick Inventory of Depressive Symptomatology (QIDS) score ≤ 5;&#xD;
&#xD;
          -  A baseline Hamilton Depression Rating Scale (HDRS) score ≤ 7;&#xD;
&#xD;
          -  Capable of providing written informed consent, and fluent in English;&#xD;
&#xD;
          -  Right-handed;&#xD;
&#xD;
          -  No first-degree relative with mood or psychotic disorder.&#xD;
&#xD;
        Exclusion Criteria (All Subjects):&#xD;
&#xD;
          -  Serious or unstable medical illness, including cardiovascular, hepatic, renal,&#xD;
             respiratory, endocrine, neurologic or hematologic disease;&#xD;
&#xD;
          -  History of seizure disorder;&#xD;
&#xD;
          -  History or current diagnosis of any of the following DSM-5 psychiatric illnesses:&#xD;
             schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not&#xD;
             otherwise specified, substance abuse disorder;&#xD;
&#xD;
          -  Clinical or laboratory evidence of hypothyroidism, hyperthyroidism, or other thyroid&#xD;
             disorder that is not controlled by medication;&#xD;
&#xD;
          -  Substance use assessed by physician as dangerous for ketamine treatment;&#xD;
&#xD;
          -  Untreated glaucoma;&#xD;
&#xD;
          -  Complex post-traumatic stress disorder (PTSD) with dissociation;&#xD;
&#xD;
          -  Patients with a lifetime history of electroconvulsive therapy (ECT).&#xD;
&#xD;
          -  Participants with a lifetime history of ketamine use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Pizzagalli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Scott, BA</last_name>
    <phone>617-855-2247</phone>
    <email>jscott@mclean.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Crowley, ALM</last_name>
    <phone>617-855-4432</phone>
    <email>djcrowley@mclean.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Lobien, BA</last_name>
      <phone>617-855-2247</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Diego A. Pizzagalli</investigator_full_name>
    <investigator_title>Director, Center for Depression, Anxiety and Stress Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

